This session traces the end-to-end arc of immunology-driven drug development - from population-scale genetics that nominate causal targets, through translational biomarker discovery and patient stratification, to late-phase clinical trials that convert hypotheses into actionable evidence.

The program highlights how statistical genetics, computational biology, and clinical biostatistics intersect to advance therapies for immune-mediated diseases.

The audience will leave with a cohesive, practical view of the genome-to-patient pipeline and concrete insights for cross-functional collaboration.